GleamWall
中文EN

VOR Vor Biopharma Inc.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1817229 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY155.3%
TTM EPS YoY177.7%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE—
ROA402.6%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets127.6%
Debt / equity—
Current ratio13.50x
Interest coverage—

Cash quality & payout

Operating cash flow / net income-0.09x
Accruals ratio438.0%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue——
R&D expense$321.53M$93.31M
SG&A expense$50.11M$27.88M
Operating income-$371.64M-$121.19M
Net income-$695.98M-$116.91M
EBITDA-$368.75M-$117.66M
EPS (basic)-70.50-34.03
EPS (diluted)-70.50-34.03
Weighted avg. shares (diluted)9.87M3.44M
Balance sheet
Cash & equivalents$396.49M$81.95M
Short-term investments$58.72M$9.98M
Current assets$458.11M$96.51M
PP&E, net$533,000$6.58M
Total assets$464.13M$142.89M
Current liabilities$25.17M$18.61M
Total liabilities$628.44M$46.23M
Shareholders' equity-$164.31M$96.66M
Shares outstanding38.72M6.24M
Cash flow statement
Operating cash flow-$142.71M-$99.66M
Capital expenditure$941,000$229,000
Free cash flow-$143.65M-$99.89M
Investing cash flow-$48.80M$96.86M
Financing cash flow$503.81M$53.39M
Depreciation & amortization$2.89M$3.53M
Stock-based compensation$18.91M$9.85M
Dividends paid$0$0

Free plan shows the latest 2 periods; Pro shows all 6 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.